Clinical Research Directory
Browse clinical research sites, groups, and studies.
Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes
Sponsor: Tan Tock Seng Hospital
Summary
This study will test whether a low-cost anti-inflammatory medicine called colchicine can help protect the blood vessels of people with type 2 diabetes. Diabetes speeds up hardening of the arteries (atherosclerosis), partly because of ongoing low-grade inflammation. Colchicine has already been shown to help prevent heart attacks and strokes in people who already have heart disease; this study looks at whether it can also help prevent early blood vessel damage before heart disease develops. Around 300 adults with type 2 diabetes will be randomly assigned to take colchicine or a placebo (dummy pill) once daily for 24 weeks, in addition to their usual diabetes and heart-risk medications. Neither participants nor the study team will know who is taking colchicine or placebo. The main measurement will be the change in the thickness of the wall of the neck (carotid) artery, measured by ultrasound, which is an early sign of blood vessel disease. The study will also look at markers of inflammation in the blood, blood vessel stiffness and function, and changes in the gut bacteria.
Official title: The Role of Colchicine in Preventing Atherosclerotic Cardiovascular Disease in Type 2 Diabetes (Col-DM Study)
Key Details
Gender
All
Age Range
21 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2025-07-24
Completion Date
2027-07-31
Last Updated
2026-09-24
Healthy Volunteers
No
Interventions
Colchicine 0.5 MG Oral Tablet Once Daily
For 24 weeks
Placebo
Matched placebo tablets (identical in size, shape, taste, and packaging to colchicine), once daily, for 24 weeks
Locations (1)
Tan Tock Seng Hospital
Singapore, Singapore, Singapore